drugset / Trial / NCT04569435
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Timeline
- Start
- 2021-01-15
- Primary completion
- 2024-01-10
- Completion
- 2024-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANX005 | Protein / enzyme biologic | — | Intravenous |